drugset / Trial / NCT03511365
Effects of Probiotic on Inflammation and Microbiota in Patients With NASH
NaSingle-groupOpen-labelBasic science
Summary
Individuals with clinically identified non-alcoholic fatty liver disease will undergo baseline evaluation of IL-17 and other inflammatory markers as well as microbiome determination. The probiotic formulation VSL#3 450 Billion CFU twice daily will be administered for 8 weeks and the determination of Il-17 and microbiome will be repeated. Each subject will serve as his or her own control.
Timeline
- Start
- 2018-05-15
- Primary completion
- 2018-12-14
- Completion
- 2019-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VSL#3 | Other / unclassified | 4.5e+11 unknown | — |